Description
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). Metformin HCl decreases hepatic glucose production through inhibition of gluconeogenesis and glycogenolysis, decrease intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Additional information
| brand | Novartis Pharmaceuticals |
|---|
